IDEX Biometrics ASA IDXAF
—
0.89
0.00
0.00%
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow IDXAF
Growth Flags
show if company had growth for consecutive years
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
22.22 | 0.10 | 8.84 | 19.34 | 119.06 | 269.93 | 231.15 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(4.01) | (0.02) | (9.92) | (11.85) | (44.07) | (46.65) | (17.03) |
P/B ratio |
6.50 | 0.02 | 3.23 | 3.46 | 8.96 | 23.62 | 5.50 |
Price to Tangible BV |
15.02 | 0.02 | 3.91 | 3.88 | 9.72 | 32.47 | 6.87 |
EV/Sales |
40.00 | 5.02 | 7.62 | 15.68 | 107.18 | 263.57 | 199.27 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.09) | (0.24) | (1.17) | (2.05) | (11.06) | (12.39) | (3.11) |
EV/FCF |
(1.11) | (0.24) | (1.16) | (2.03) | (11.00) | (12.31) | (3.11) |
Quick Ratio |
0.24 | 0.85 | 1.07 | 3.66 | 8.22 | 2.15 | 2.98 |
Current Ratio |
1.58 | 2.67 | 1.64 | 4.74 | 8.71 | 2.60 | 3.27 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.20 | 0.50 | 1.14 | 0.28 | 0.44 |
Debt/Assets |
10.00% | 19.26% | 25.29% | 3.94% | 0.03% | 1.92% | 2.60% |
Debt/Equity |
0.52 | 0.42 | 0.56 | 0.05 | 0.00 | 0.03 | 0.03 |
Asset Turnover |
0.03 | 0.05 | 0.15 | 0.12 | 0.10 | 0.05 | 0.00 |
Operating CF/Net income |
0.86 | 1.21 | 1.01 | 0.96 | 0.85 | 0.87 | 0.84 |
Capex/Depreciation |
(0.09) | 0.05 | (0.15) | (0.20) | (0.08) | (0.19) | (0.52) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (323.95%) | (180.08%) | (155.84%) | (107.86%) | (129.59%) | (176.44%) | 0.00% | |
| (111.54%) | (81.96%) | (98.67%) | (91.95%) | (110.29%) | (132.20%) | 0.00% | |
ROIC |
(436.26%) | (292.20%) | (266.50%) | (249.48%) | (492.68%) | (297.70%) | (466.23%) |
Return on Tangible Assets |
(378.58%) | (244.24%) | (304.89%) | (164.06%) | (94.74%) | (320.79%) | (242.32%) |
Average Days of Receivables |
527.38 | 404.06 | 170.06 | 203.24 | 193.30 | 550.00 | 691.26 |
Research and Development Expense of Revenue |
536.22% | 292.15% | 57.83% | 79.44% | 94.37% | 173.06% | 1,034.20% |
Selling, General and Administrative Expense of Revenue |
1,043.31% | 1,046.02% | 345.70% | 469.64% | 743.20% | 1,613.88% | 5,129.72% |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.08 | 0.08 | 0.07 | 0.20 | 0.15 |
Share Based Compensation of Revenue |
(185.04%) | 41.74% | 31.01% | 66.51% | 96.83% | 251.60% | 596.93% |
Graham Net Nets |
0.02 | 44.27 | 0.18 | 0.22 | 0.10 | 0.02 | 0.11 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(67.05%) | (17,829.00%) | (73.48%) | (38.93%) | (13.59%) | (10.38%) | (31.50%) |
Free Cash Flow Yield |
(162.62%) | (21,005.16%) | (74.52%) | (39.98%) | (8.18%) | (7.93%) | (27.72%) |
Revenue per Share |
0.01 | 0.20 | 1.64 | 1.99 | 1.55 | 0.71 | 0.35 |
Operating CF per Share |
(0.22) | (4.23) | (10.67) | (15.27) | (14.98) | (15.18) | (22.70) |
Capex per Share |
0.00 | 0.03 | (0.10) | (0.13) | (0.08) | (0.22) | (0.71) |
Free Cash Flow per Share |
(0.22) | (4.20) | (10.77) | (15.40) | (15.06) | (15.40) | (23.41) |
Cash per Share |
0.02 | 0.49 | 4.49 | 7.85 | 18.37 | 4.76 | 11.80 |
Shareholders Equity per Share |
0.04 | 1.14 | 4.48 | 11.12 | 20.53 | 8.16 | 14.88 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.04 | 1.14 | 4.48 | 11.12 | 20.53 | 8.16 | 14.88 |
Free Cash Flow |
(8.64) | (17.42) | (27.25) | (31.64) | (27.67) | (23.63) | (28.02) |
Working Capital |
2.60 | 5.79 | 7.92 | 18.80 | 33.06 | 6.67 | 11.37 |
Capital Expenditures |
(0.04) | 0.11 | (0.24) | (0.27) | (0.14) | (0.33) | (0.85) |
Net Current Asset Value |
0.88 | 3.67 | 6.68 | 17.66 | 33.05 | 6.35 | 10.73 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.17 | (0.14) | 0.06 | 0.07 | 0.05 | 0.30 | 2.00 |
Net Profit Margin |
(3,937.80%) | (1,718.07%) | (643.52%) | (798.39%) | (1,146.20%) | (2,443.29%) | (7,646.93%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
11.40 | 20.63 | 2.01 | 1.22 | 1.39 | 1.03 | 0.81 |
Cash ROIC |
(294.05%) | (202.78%) | (95.92%) | (80.98%) | (40.33%) | (123.94%) | (89.66%) |
Accounts Receivable Turnover |
0.39 | 0.59 | 1.97 | 2.16 | 1.80 | 0.89 | 0.00 |
Accounts Payable Turnover |
0.61 | 2.19 | 3.51 | 2.92 | 1.91 | 0.50 | 0.00 |
Inventory Turnover |
0.11 | 0.28 | 0.72 | 1.14 | 1.20 | 0.36 | 0.00 |
Average Days of Payables |
690.64 | 184.23 | 64.26 | 173.27 | 199.38 | 837.51 | 2,725.73 |
Days of Inventory on Hand |
3,388.77 | 1,202.51 | 596.25 | 500.36 | 359.18 | 1,140.13 | 4,038.55 |
Average Receivables |
0.65 | 1.43 | 2.10 | 1.89 | 1.58 | 1.23 | — |
Average Payables |
1.00 | 0.77 | 1.11 | 1.11 | 0.66 | 0.55 | — |
Average Inventory |
5.62 | 5.97 | 5.42 | 2.84 | 1.05 | 0.77 | — |
Average Assets |
8.97 | 17.63 | 26.99 | 35.52 | 29.52 | 20.24 | — |
Average Common Equity |
3.09 | 8.02 | 17.09 | 30.28 | 25.12 | 15.16 | — |
Columns are period end dates